Repligen (RGEN) Cash & Equivalents (2010 - 2026)

Repligen (RGEN) has 17 years of Cash & Equivalents data on file, last reported at $784.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 12.52% year-over-year to $784.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $784.5 million (up 12.52% YoY) and the FY2025 annual result came in at $566.0 million, down 25.29% from the prior year.
• Cash & Equivalents advanced to $784.5 million in Q1 2026 per RGEN's latest filing, from $566.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $809.1 million in Q2 2024 and bottomed at $516.6 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $697.2 million (2025), against an average of $671.6 million.
• The widest annual swing landed in 2024, when Cash & Equivalents surged 51.1%; it then fell 25.29% in 2025.
• Tracing RGEN's Cash & Equivalents over 5 years: stood at $523.5 million in 2022, then surged by 43.53% to $751.3 million in 2023, then increased by 0.84% to $757.6 million in 2024, then slipped by 25.29% to $566.0 million in 2025, then soared by 38.6% to $784.5 million in 2026.
• Per Business Quant, the three latest RGEN Cash & Equivalents figures stand at $784.5 million (Q1 2026), $566.0 million (Q4 2025), and $748.7 million (Q3 2025).

Peer Comparison